The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | First-in-human study of the oral CLK inhibitor BH-30236 in adults with R/R AML or HR-MDS
Eytan Stein, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the first-in-human study (NCT06501196) investigating the oral CDC-like kinase (CLK) inhibitor BH-30236 as monotherapy or in combination with venetoclax in adults with relapsed/refractory (R/R) acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (HR-MDS). Dr Stein highlights that BH-30236 monotherapy is well tolerated and reduces blast counts, while combining the agent with venetoclax has led to notable responses and complete remissions, even in patients previously exposed to venetoclax. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
